Kemin Industries, a global ingredient manufacturer based in Des Moines, with its subsidiary Kemin Biologics, has signed an exclusive agreement with Pacific GeneTech to license PGT's TMH001 Eimeria vaccine for poultry. PGT is a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in animal health and food safety. As part of its partnership with PGT, Kemin will focus on developing the Eimeria vaccine and registering it in the United States and in other countries, beginning with the European Union. Kemin will also expand the Eimeria vaccine's availability to Asia, the Middle East, Africa and Latin America. Eimeria is an intestinal parasite that can infect poultry. "Kemin sees great potential in the marketplace for innovative vaccines and is dedicated to improving the health of poultry and livestock, which ensures the safety of our global food supply," said Chris Nelson, president and CEO of Kemin Industries. "This new agreement with Pacific GeneTech continues our advancement in providing next-generation vaccines that have the ability to transform the quality of life around the world."